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INTRODUCTION 
Stem cell treatments are a type of genetic medicine that 
introduces new cells into damaged tissue in order to treat a 
disease or injury. Many medical researchers believe that 
stem cell treatments have the potential to change the face 
of human disease and alleviate suffering. The ability of 
stem cells to self-renew and give rise to subsequent 
generations that can differentiate 
1
 offers a large potential 
to culture tissues that can replace diseased and damaged 
tissues in the body, without the risk of rejection and s ide 
effects. 
A number of stem cell treatments exist, although most are 
still experimental and/or costly, with the notable exception 
of bone marrow transplantation. Medical researchers 
anticipate one day being able to use technologies derived 
from adult and embryonic stem cell research to treat 
cancer, Type 1 diabetes mellitus , Parkinson's disease, 
Huntington's disease, Celiac Disease, cardiac failure, 
muscle damage and neurological disorders, along with 
many others.
2 
Stem cell research holds great promise for improving 
human health by control of degenerative diseases and 
restoration of damage to organs  by various injuries; but at 
the same time it also raises several ethical and social issues 
such as destruction of human embryos to create human 
embryonic stem (hES) cell lines, potential for introducing 
commodification in human tissues and organs with 
inherent barriers of access to socioeconomically deprived 
and possible use of technology for germ-line engineering 
and reproductive cloning. The research in this field, 
therefore, needs to be regulated to strike a balance.  
Of utmost importance is assurance of safety and rights of 
those donating gametes/ blastocysts/ somatic cells for 
derivation of stem cells; or fetal t issues/umbilical cord  
cells/ adult tissue (or cells) for use as stem cells.  
Safeguards have also to be in place to protect research 
participants receiving stem cell transplants, and patients at 
large from unproven therapies/remedies. W ith success of 
growing human embryonic stem cells without feeder layer, 
derivation of histocompatible hES from embryos created 
by Somatic Cell Nuclear Transfer (SCNT) and tissue 
specific differentiation of umbilical cord/bone marrow 
derived mesenchymal and haematopoeitic stem cells, there 
is a need to generate public confidence in potential benefit 
of stem cell research to human health and disease. As stem 
cell therapy is poised to enter into clinical practice, there is 
an urgent need to formulate guidelines for Stem cell  
Research and Therapy (SCRT).
3
 
OVERVIEW OF BAS IC RES EARCH 
Most cells within an animal or human being are committed 
to fulfilling a single function within the body. In contrast, 
stem cells are a unique and important set of cells that are 
not specialized. Stem cells retain the ability to become 
many or all of the different cell types in the body and 
thereby play a critical role in repairing organs and body 
tissues throughout life. Although the term stem cells is 
often used in reference to these repair cells within an adult 
organism, a more fundamental variety of stem cells is 
found in the early stage embryo. Embryonic stem cells 
may have a greater ability to become different types of 
body cells than adult stem cells.
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Stem Cells from Embryos or Fetal Tissue  
Embryonic stem cells were first isolated from mouse 
embryos in 1981. Animal embryos were the only source 
for research on embryonic stem cells until November 
1998, when two groups of U.S. scientists announced the 
successful isolation of human embryonic stem cells. One  
group, at the University of Wisconsin, derived stem cells 
from one-week-old embryos produced via in vitro 
fertilization (IVF).1 The work is controversial, in the 
opinion of some indiv iduals, because the stem cells are 
located within the embryo and the process of removing 
them destroys the embryo. The second group, at Johns 
Hopkins University, derived cells with very similar 
properties from five- to nineweek- old embryos or foetuses 
obtained through elective abortion.
2
 Both groups reported 
the human embryos or foetuses were donated for research 
following a process of informed consent. The cells were 
then manipulated in the laboratory to create embryonic 
stem cell lines that may continue to divide for many 
months to years. Another potential source of embryonic 
stem cells is somatic cell nuclear transfer (SCNT), also 
referred to as cloning.3 In SCNT the nucleus of an egg is 
removed and replaced by the nucleus from a mature body 
cell, such as a skin cell. The cell created via SCNT is 
allowed to develop for a week and then the stem cells are 
removed. In 1996, scientists in Scotland used the SCNT 
procedure to produce Dolly the sheep, the first mammalian  
clone.4 In February 2004, Korean scientists announced 
that they had created human embryos via the SCNT 
process and had succeeded in isolating human stem cells 
from a cloned embryo. This development and the 
unsubstantiated announcement by Clonaid in December 
2002 of the birth of a cloned child have contributed to the 
controversy over research on human embryos. 
Stem Cells from Adult Tissue or Umbilical Cord Blood 
Stem cells obtained from adult organisms are also the 
focus of research. There have been a number of recent 
publications on adult stem cells from a variety of different 
sources, such as bone marrow and the umbilical cord 
following birth. In addition, a number of private 
companies (such as MorphoGen, NeuralStem, Osiris 
Therapeutics, Stem Source, ViaCell) are working on 
therapeutic uses of adult stem cells. Some advocate that 
adult instead of embryonic stem cell research should be 
pursued because they believe the derivation of stem cells 
from either IVF embryos or aborted foetuses is ethically  
unacceptable. Others believe that adult stem cells  should 
not be the sole target of research because of important 
scientific and technical limitations. Adult stem cells may  
not be as long lived or capable of as many cell divisions as 
embryonic stem cells. Also, adult stem cells may not be as 
versatile in developing into various types of tissue as 
embryonic stem cells, and the location and rarity of the 
cells in the body might rule out safe and easy access. For 
these reasons, many scientists argue that both adult and 
embryonic stem cells should be the subject of research, 
allowing fo r a comparison of their various capabilities.  
Classification of human stem cells
6
 
On the basis of their orig in three groups of stem cells are 
recognized: 
A.  Human embryonic stem (hES) cells, derived from 
blastocysts: 
a) Blastocysts derived from surplus embryos from IVF 
clin ics. 
b) Blastocysts derived specifically for research or 
therapy using IVF. 
c) Blastocysts derived by other techniques like SCNT 
etc. 
B.  Human embryonic germ (hEG) cells, which are derived 
from primordial germ cells of the foetus. 
D. Human somatic stem (hSS) cells, which are derived 
from fetal or adult tissues or organs, including umbilical 
cord blood / placenta. 
 
Figure 1: A Human Stem Cell 
SOURCES AND CHARACTERIS TICS OF HUMAN 
STEM CELLS  
Human Embryonic Stem Cells: The study of human stem 
cells has barely begun and what is known is summarized in  
this section. The vast majority of experimental data 
discussed here are the results of experiments in mice. ES 
cells from the mouse have been intensely investigated 
since their discovery 18 years ago. Therefore, what is said 
about human ES cells assumes in part that their 
fundamental properties will resemble those of mouse ES  
cells. While on the surface this assumption appears to be 
reasonable it will have to be proven through intensive 
further investigation. There is an abundance of stem cell 
lines from mammals including some from human beings. 
ES cells are valuable scientifically because they combine 
three properties not found together in other cell lines. First, 
they appear to replicate indefinitely without undergoing 
senescence (aging and death) or mutation of the genetic 
material. They are thus a large-scale and valuable source 
of cells. Second, ES cells appear genetically normal, both 
by a series of genetic tests and functionally as shown by 
the creation of mice with genomes derived entirely from 
ES cells. In mice these cells are developmentally  
totipotent; when inserted into an early embryo, they join  
the host cells to create a normal mouse, differentiating into 
every cell type of the body (it is this property that earns 
them the name “stem cell of the body”). ES cells can also 
differentiate into many cell types in tissue culture, 
including neurons, blood cells and cardiac and skeletal  
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muscle. The normal embryo has about 100 cells with the 
properties of ES cells that exist for about one day and then 
develop into more advanced cell types. The isolation and 
subsequent growth of ES cells in culture allow scientists to 
obtain millions of these cells in a single tissue culture 
flask, making something once rare and precious now 
readily available to researchers. It is worth noting here the 
striking parallel to recombinant DNA and monoclonal 
antibody technologies, both of which have amplified rare 
and precious biological entities. Like those technologies, 
ES cell technology may well be transformat ive in opening 
scientific arenas that to date have been closed. 
The isolation, culture, and partial characterization of stem 
cells isolated from human embryos was reported in 
November of 1998.
7
 The ability of the cells to maintain  
their pluripotent character even after 4 to 5 months of 
culturing was demonstrated.2 There is  concern that this 
feature of these cells could also lead to cancerous growth. 
Thus far there are no data indicating the induction of 
malignant tumours, although there is some evidence for 
benign hyper proliferat ion (overgrowth of cells).
8 
 
Human Embryonic Germ Cells:  
Embryonic germ cells are derived from primordial  
germline cells in early foetal tissue during a narrow 
window of development. Unlike embryonic stem cells, 
animal experiments on embryonic germ cells have been 
limited. In November of 1998, the isolation, culture, and 
partial characterization of germ cells  derived from the 
gonadal ridge of human tissue obtained from abortuses 
was reported.
9 
These experiments showed that these EG 
cells are capable of forming the three germ layers that 
make all the specific organs of the body. There are fewer 
data from an imal EG cell experiments than from ES cell 
experiments, but it is generally assumed that the range of 
potential fates will be relatively limited compared to ES 
cells, because the EG cells are much further along in  
development (5-9 weeks as opposed to 5 days in the 
published experiments). Foetal tissue may provide 
committed neural progenitors, but the feasibility of large 
scale sourcing and manufacturing of products utilizing 
such cells is questionable. Furthermore, the behaviour of 
these cells in vivo is not well understood; significant 
research will be required to avoid unwanted outcomes, 
including ectopic tissue format ion (additional, unwanted 
tissue), tumor induction, or other abnormal development.
10
 
Human adult stem cells  
From post-embryonic development through the normal life 
of any organism, certain tissues of the body require stem 
cells for normal turnover and repair. Stem cells that are 
found in developed tissue, regardless of the age of the 
organism at the time, are referred to as adult stem cells  
(Fig. 1). The most well-known example of this are the 
hematopoietic stem cells of blood.
11
 More recently, 
mesenchymal stem cells  (MSC) required for the 
maintenance of bone, muscle, and other tissues have 
beendiscovered.
12 
Adult stem cells are multipotent; the 
number of tissues that they can regenerate compares 
poorly with the pluripotency of embryonic stem cells and 
embryonic germ cells. However, the MSC is in fact an 
excellent example of the potential for use of stem cells in 
human therapeutic procedures. MSCs are capable of 
differentiating into bone, cartilage, muscle, fat, and a few 
other tissue types. Their use for bone and cartilage 
replacement is undergoing FDA-approved clin ical t rials at 
the present time.
 
 
Figure 2: Multipotent Stem Cells  
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Adult-derived stem cell therapies will co mplement, but 
cannot replace, therapies that may be eventually obtained 
from ES cells. They do have some advantages. For 
example, adult stem cells offer the opportunity to utilize 
small samples of adult tissues to obtain an initial culture of 
a patient’s own cells for expansion and subsequent 
implantation (this is  called an autologous transplant). This 
process avoids any ethical or legal issues concerning 
sourcing, and also protects the patient from viral, bacterial, 
or other contamination from another individual. With 
proper manufacturing quality controls and testing, 
allogeneic adult stem cells (cells from a donor) may be 
practical as well. A lready in clin ical use are autologous 
and allogeneic transplants of hematopoietic stem cells that 
are isolated from mobilized peripheral b lood or from bone 
marrow by positive selection with antibodies in 
commercial devices. In general, there is less ethical 
concern over their initial source. Additionally, since they 
normally differentiate into a narrower set of cell types, 
directing them to a desired fate is more straightforward. 
However, many cells of medical interest cannot, as of yet, 
be obtained from adult-derived cell types. Production of 
large numbers of these cells is much more difficult than is 
the case for ES ce lls. Based upon our present knowledge 
base, it appears unlikely that human adult stem cells alone 
will provide the entire necessary cell types required for the 
most clinically important areas  of research. 
Possible Sources of Stem Cells  
 Embryos created via IVF (for infert ility treatment or 
for research purposes) 
 Embryos or foetuses obtained through elective 
abortion 
 Embryos created via SCNT (somatic cell nuclear 
transfer, or clon ing) 
 Adult tissues (bone marrow, umbilical cord b lood) 
Spiritual and Religious Contexts 
Two broad and somewhat opposing themes characterize 
the response of most religious  communities and traditions 
to the promising new biomedical technology that stem cell  
research represents. On the one hand, there is a moral 
commitment to healing and to relieving suffering caused 
by injury and illness. For bib lically-based traditions, this 
commitment reflects a responsibility to serve as partners 
with God and stewards of God’s  creation. Because of this 
commitment, most religious communit ies applaud the 
promise of stem cell research for enhancing scientific 
understanding of human development; for probing the 
cellu lar orig ins of cancer, diabetes, spinal cord injury, 
arthritis, and a host of other lethal or disabling illnesses 
and conditions; for developing more effective 
pharmacological drugs; and for pursuing successful tissue 
and organ transplant technology. On the other hand, most 
traditions also warn that human beings are not God. 
Humans lack omniscience and our pursuits are often 
tainted by selfishness. With regard to stem cell research, 
this suggests the need to be cautious in pursuing the 
promise of this research and to strive to anticipate and 
minimize its potential harms and misuses. These include 
direct harms to the donors of the tissues and embryos from 
which stem cells may be derived and harms to future 
research subjects exposed to the unknown risks of stem 
cell implants. It also includes possible longer-term harms  
to society ranging from damage to our respect for the 
sanctity of human life to inequities resulting from the 
appropriation or privatization of a resource with great 
potential to benefit everyone. 
Beyond these two broadly shared themes, there is 
significant disagreement among American religious 
communit ies over some of the specific moral issues raised 
by stem cell research. The most medically promising stem 
cells, with a capacity to differentiate into any of the human 
body’s cell types, are derived either from the inner cell 
mass of pre-implantation embryos (ES cells) or from the 
gonadal tissue of aborted foetuses (EG lls). Both of these 
sources involve extraction and manipulation of cells from 
human embryos or foetuses. This raises issues of 
fundamental importance for some religious  communit ies 
and can profoundly engage the conscience of Americans. 
There are two principal areas of disagreement. One 
concerns the question of whether it is  ever morally  
appropriate to destroy an embryo and whether the benefits 
of research provide a justification for doing so. At issue 
here is the question of whether the human embryo (or 
foetus in the case of EG cells) possesses significant moral 
status and must be protected from harm. Among those who 
answer this in the affirmative, a second question and some 
further disagreements arise. This is the question of whether 
researchers who have played no part in the destruction of 
an embryo or fetus may  ethically utilize cellular materials 
produced in these ways. This is the question of when, if 
ever, it is morally permissible to cooperate with or benefit 
from what some persons regard as evil acts. The first of 
these questions is among the most controversial in our 
society. Some religious communities believe the embryo 
or fetus is a full human being from the moment of  
conception, since it is genetically human and has  the 
potential for development into a human individual.15 
Other tradit ions take a “developmental” v iew of 
personhood, believing that the early embryo or foetus only 
gradually becomes a full human being and thus may not be 
entitled to the same moral protections as it will later.16 
Still others hold that while the embryo represents human 
life, that life may be taken for the sake of saving and 
preserving other lives in the future.17 
It is noteworthy that, despite these differences, all these 
positions can support research that does not involve the use 
of embryonic or fetal cells, that is to say, adult stem cell  
research. Opponents of abortion also support the use of 
foetal tissues when these result from stillb irths or 
miscarriages. They object only to the deliberate destruction 
of foetuses or embryos. Unfortunately, these zones of 
agreement do not include some promising areas of stem 
cell research, those involving the use of cells obtained 
from embryos (ES cells), or from deliberately aborted 
foetuses (EG cells). The fact that much basic research 
needs to be done in the area of human embryonic 
development suggests that both ES and EG cells will 
continue to play an important role in future research 
endeavours. Where germ cells are concerned, spontaneous 
abortions or stillbirths are a poor source of the tissue, both 
because the collection of the tissue requires substantial 
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preparation, the critical t ime period is of short duration, 
and because, with spontaneous abortions particularly, this 
tissue is likely to suffer from genetic abnormalit ies. While 
continuing research efforts must be made to understand the 
biology of alternative sources of such cells, adult stem 
cells cannot entirely replace either EG and ES cells 
because much basic research needs to be done in the area 
of early human embryonic development for which EG and 
ES cells are required. 
The zone of agreement is somewhat widened, however, 
when we recognize that some who adamantly oppose the 
destruction of embryos or foetuses can accept the view that 
research on the cellular materials remain ing from such acts 
is not always unethical. These individuals take the view 
that not all acts benefiting from others’ wrongdoing are 
morally impermissible, so long as one is not in any way 
involved in the wrongdoing and one’s own acts do not 
foster, encourage, or lend support to it. For some who hold 
this moral position, no involvement with foetal or embryo 
destruction can meet this test, as all such involvement 
amounts to wrongful cooperation with evil.18 However, 
others equally opposed to embryo destruction may 
conclude differently.19 
Despite the possibility of achieving some consensus in 
these directions, important disagreements remain. Some 
who hold the view that full moral protection begins at 
conception will conclude that their religious and ethical 
perspective requires them to oppose any federal 
involvement in stem cell research so long as embryo or 
foetal destruction is involved, and they may even believe 
that all activ ities of this sort should be prohibited. Others, 
drawing on their own religious beliefs, will determine that 
stem cell research is not only ethically permitted, but 
required in the name of promoting human health. 
POTENTIAL APPLICATIONS OF STEM CELL 
RES EARCH.
14 
 Stem cells provide the opportunity to study the growth 
and differentiation of indiv idual cells into tissues. 
Understanding these processes could provide insights into 
the causes of birth defects, genetic abnormalities, and other 
disease states. If normal development were better 
understood, it might be possible to prevent or correct some 
of these conditions. Stem cells could be used to produce 
large amounts of one cell type to test new drugs for 
effectiveness and chemicals for toxicity. Stem cells might 
be transplanted into the body to treat disease (diabetes, 
Parkinson’s disease) or injury (e.g., spinal cord). The  
damaging side effects of medical treatments might be 
repaired with stem cell treatment. For example, cancer 
chemotherapy destroys immune cells in patients, 
decreasing their ability to fight off a broad range of 
diseases; correcting this adverse effect would be a major 
advance. 
Before stem cells can be applied to human medical 
problems, substantial advances in basic cell bio logy and 
clin ical technique are required. In addition, very  
challenging regulatory decisions will be required on the 
individually created tissue based therapies resulting from 
stem cell research. Such decisions would likely be made 
by the Center for Bio logics Evaluation and Research 
(CBER) of the Food and Drug Administration (FDA). The 
potential benefits mentioned above would be likely only 
after many more years of research. Technical hurdles 
include developing the ability to control the differentiat ion 
of stem cells into a desired cell type (like a heart or nerve 
cell) and to ensure that uncontrolled development, such as 
a cancerous tumor, does not occur. If stem cells are to be 
used for transplantation, the problem of immune reject ion 
must also be overcome. Some scientists think that the 
creation of many more embryonic stem cell lines will 
eventually account for all the various  immunological types 
needed for use in tissue transplantation therapy. Others 
envision the eventual development of a “universal donor” 
type of stem cell tissue, analogous to a universal blood 
donor. 
However, if the SCNT technique (cloning) was employed 
using a cell nucleus from the patient, stem cells created via 
this method would be genetically identical to the patient, 
would presumably be recognized by the patient’s immune 
system, and thus would avoid any tissue rejection 
problems that could occur in other stem cell therapeutic 
approaches. Because of this, many scientists believe that 
the SCNT technique may provide the best hope of 
eventually treating patients using stem cells  for tissue 
transplantation. 
APPLICATIONS OF STEM CELLS IN 
TREATMENT OF DES EAS ES : 
Brain damage 
Stroke and traumatic brain in jury lead to cell death, 
characterized by a loss of neurons and  ligodendrocytes 
within the brain. Healthy adult brains contain neural stem 
cells which divide and to maintain general stem cell 
numbers, or become progenitor cells . In healthy adult 
animals, progenitor cells migrate within the brain and 
function primarily to maintain neuron populations for 
olfaction (the sense of smell). Interestingly, in pregnancy 
and after injury, this system appears to be regulated by 
growth factors and can increase the rate at which new 
brain matter is formed. In the case of brain in jury, although 
the reparative process appears to initiate, substantial 
recovery is rarely observed in adults, suggesting a lack of 
robustness. Stem cells may also be used to treat brain 
degeneration, such as in Parkinson's and Alzheimer's 
disease.
15,16 
Cancer 
Research injecting neural (adult) stem cells into the brains 
of dogs has shown to be very successful in treat ing 
cancerous tumors. With traditional techniques brain cancer 
is almost impossible to treat because it spreads so rapidly. 
Researchers at the Harvard Medical School induced 
intracranial tumours in rodents. Then, they injected human 
neural stem cells. Within days the cells had migrated into 
the cancerous area and produced cytosine deaminase, an 
enzyme that converts a non-toxic pro-drug into a 
chemotheraputic agent. As a result, the injected substance 
was able to reduce tumor mass by 81 percent. The stem 
cells neither differentiated nor turned tumorigenic.
17
 Some 
researchers believe that the key to finding a cure for cancer 
is to inhibit cancer stem cells, where the cancer tumor 
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originates. Currently, cancer treatments are designed to kill 
all cancer cells, but through this method, researchers 
would be able to develop drugs to specifically target these 
stem cells.
18 
Spinal cord injury 
A team of Korean researchers reported on November 25, 
2003, that they had transplanted mult ipotent adult stem 
cells from an umbilical cord b lood to a patient suffering 
from a spinal cord injury and that she can now walk on her 
own, without difficu lty. The patient had not been able to 
stand up for roughly 19 years. For the unprecedented 
clin ical test, the scientists isolated adult stem cells from 
umbilical cord b lood and then injected them into the 
damaged part of the spinal cord.
19
 
[20
 
According to the October 7, 2005 issue of The Week , 
University of California  researchers injected human 
embryonic stem cells into paralyzed mice, which resulted 
in the mice regaining the ability to move and walk four 
months later. The researchers discovered upon dissecting 
the mice that the stem cells regenerated not only the 
neurons, but also the cells of the myelin sheath, a layer of 
cells which insulates neural impulses and speeds them up, 
facilitating communication with the brain (damage to 
which is often the cause of neurological injury in humans). 
In January 2005, researchers at the University of 
Wisconsin–Madison differentiated human blastocyst stem 
cells into neural stem cells, then into the beginnings of 
motor neurons, and finally into spinal motor neuron cells, 
the cell type that, in the human body, transmits messages 
from the brain to the spinal cord. The newly generated 
motor neurons exhibited electrical activity, the signature 
action of neurons. Lead researcher Su-Chun Zhang 
described the process as "you need to teach the blastocyst 
stem cells to change step by step, where each step has 
different conditions and a strict window of time."  
Transforming blastocyst stem cells into motor neurons had 
eluded researchers for decades. The next step will be to 
test if the newly generated neurons can communicate with 
other cells when transplanted into a living animal; the first 
test will be in chicken embryos. Su-Chun said their trial-
and-error study helped them learn how motor neuron cells, 
which are key to the nervous system, develop in the first 
place. The new cells could be used to treat diseases like 
Lou Gehrig's disease, muscular dystrophy, and spinal cord 
injuries. 
Heart damage 
Several clinical trials targeting heart disease have shown 
that adult stem cell therapy is safe and effective, and is 
equally efficient in old as well as recent infarcts. 
21
 Adult 
stem cell therapy for heart disease was commercially  
available on at least five continents at the last count 
(2007). 
Possible mechanis ms are:
15
 
 Generation of heart muscle cells  
 Stimulation of growth of new blood vessels that 
repopulate the heart tissue 
 Secretion of growth factors, rather than actually 
incorporating into the heart 
 Assistance via some other mechanism 
It may be possible to have adult bone marrow cells 
differentiate into heart muscle cells.
[15] 
Haematopoiesis (blood cell formation) 
The specificity of the human immune cell repertoire is 
what allows the human body to defend itself from rapidly  
adapting antigens. However, this system is a hot spot for 
degradation upon the pathogenesis of disease, and because 
of the critical role that it plays in organismal defense, its 
degradation is often fatal to the system as a whole. 
Diseases of hematopoietic cells are called  
hematopathology. The specificity of the immune cells is 
what allows them to recognize foreign antigens, causing 
further challenges in the treatment of immune disease. 
Identical matches between donor and recipient must be 
made for successful transplantation treatments, while 
matches are uncommon, even between first-degree 
relatives. Research using both hematopoietic adult stem 
cells and embryonic stem cells has contributed great 
insight into possible mechanisms and methods of treatment 
for many of these ailments. 
Fully mature human red blood cells may be generated ex 
vivo by hematopoietic stem cells  (HSCs), which are 
precursors of red blood cells. In this process, HSCs are 
grown together with stromal cells, creating an environment 
that mimics the conditions of bone marrow, the natural site 
of red blood cell growth. Erythropoietin, a growth factor, 
is added, coaxing the stem cells to complete terminal 
differentiation into red blood cells.
22
 Further research into 
this technique should have potential benefits to gene 
therapy, blood transfusion, and topical medicine.  
Baldness 
Hair follicles also contain stem cells, and some researchers 
predict research on these follicle stem cells may lead to 
successes in treating baldness through "hair 
multip licat ion", also known as "hair cloning". This 
treatment is expected to work through taking stem cells 
from existing follicles, multiply ing them in cultures, and 
implanting the new follicles into the scalp. Later 
treatments may be able to simply signal follicle stem cells 
to give off chemical signals to nearby follicle cells which 
have shrunk during the aging process, which in turn  
respond to these signals by regenerating and once again 
making healthy hair. 
23 
Missing teeth 
In 2004, scientists at King's College London discovered a 
way to cultivate a complete tooth in mice
24
 and were able 
to grow them stand-alone in the laboratory. Researchers 
are confident that this technology can be used to grow live 
teeth in human patients. 
In theory, stem cells taken from the patient could be 
coaxed in the lab into turning into a tooth bud which, when 
implanted in the gums, will give rise to a new tooth, which 
would be expected to take two months to grow.
25
 It will 
fuse with the jawbone and release chemicals that 
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encourage nerves and blood vessels to connect with it . The 
process is similar to what happens when humans grow 
their orig inal adult teeth. Many challenges remain, 
however, before stem cells could be a choice for the 
replacement of missing teeth in the future.
26 
Deafness 
There has been success in re-growing cochlea hair cells 
with the use of stem cells.
27 
Blindness and vision impairment 
Since 2003, researchers have successfully transplanted 
retinal stem cells into damaged eyes to restore vision. 
Using embryonic stem cells , scientists are able to grow a 
thin sheet of totipotent stem cells in the laboratory. When 
these sheets are transplanted over the damaged retina, the 
stem cells stimulate renewed repair, eventually restoring 
vision.
28
 The latest such development was in June 2005, 
when researchers at the Queen Victoria Hospital of Sussex, 
England were able to restore the sight of forty patients 
using the same technique. The group, led by Dr. Sheraz 
Daya, was able to successfully use adult stem cells 
obtained from the patient, a relative, or even a cadaver. 
Further rounds of trials are ongoing.
29
 
In April 2005, doctors in the UK transplanted corneal stem 
cells from an organ donor to the cornea of Deborah Catlyn, 
a woman who was blinded in one eye when an acid was 
thrown in her eye at a nightclub. The cornea, which is the 
transparent window of the eye, is a particularly suitable 
site for transplants. In fact, the first successful human 
transplant was a cornea transplant. The cornea has the 
remarkable property that it does not contain any blood 
vessels, making it relat ively easy to transplant. The 
majority of corneal transplants carried out today are due to 
a degenerative disease called keratoconus. 
The University Hospital of New Jersey claims a success 
rate growing the new cells from transplanted stem cells 
varies from 25 percent to 70 percent.
30
 In 2009, researchers 
at the University of Pittsburgh Medical center 
demonstrated that stem cells collected from human corneas 
can restore transparency without provoking a rejection 
response in mice with corneal damage.
[31]
 
Amyotrophic lateral sclerosis 
Stem cells have cured rats with an Amyotrophic lateral 
sclerosis-like d isease. The rats were injected with a virus 
to kill the spinal cord motor nerves related to leg 
movement, succeeded by injections of stem cells into their 
spinal cords. These migrated (passed through many layers 
of tissues) to the sites of injury where they were able to 
regenerate the dead nerve cells restoring the rats which 
were once again able to walk.
32 
Graft vs. host disease and Crohn's disease 
Phase III clinical trials expected to end in second-quarter 
2008 were conducted by Osiris Therapeutics using their in-
development product Prochymal, derived from adult bone 
marrow. The target disorders of this therapeutic are graft-
versus-host disease and Crohn's disease.
33 
Neural and behavioral birth defects  
A team of researchers led by Prof. Joseph Yanai were able 
to reverse learning deficits in  the offspring of pregnant 
mice who were exposed to heroin and the pesticide 
organophosphate. This was done by direct neural stem cell 
transplantation into the brains of the offspring. The 
recovery was almost 100 percent, as proved in behavioral 
tests in which the treated animals improved to normal 
behavior and learning scores after the transplantation. On 
the molecular level, brain chemistry of the treated animals 
was also restored to normal. Through the work, which was 
supported by the US National Institutes of Health, the US-
Israel Binational Science Foundation and the Israel anti-
drug authorities, the researchers discovered that the stem 
cells worked even in cases where most of the cells died out 
in the host brain. 
The scientists found that before they die the neural stem 
cells succeed in inducing the host brain to produce large 
numbers of stem cells which repair the damage. These 
findings, which answered a major question in the stem cell 
research community, were published earlier this year in the 
leading journal, Molecular Psychiatry. Scientists are now 
developing procedures to administer the neural stem cells 
in the least invasive way possible - probably via blood 
vessels, making therapy practical and clinically feasible. 
Researchers also plan to work on developing methods to 
take cells from the patient's own body, turn them into stem 
cells, and then transplant them back into the patient's blood 
via the blood stream. Aside from decreasing the chances of 
immunological rejection, the approach will also eliminate 
the controversial ethical issues involved in the use of stem 
cells from human embryos.
34 
Diabetes 
Diabetes patients lose the function of their insulin-
producing beta cells of their pancreas. Human embryonic 
stem cells may be grown in cell culture and stimulated to 
form insulin-producing cells that can be transplanted into 
the patient. 
However, success depends on developing procedures in all 
required steps:
 15
 
 Have the cells proliferate and generate sufficient 
amount of tissue 
 Differentiation into the right cell type 
 Survival o f the cells in the recip ient (prevention of 
transplant rejection) 
 Integration with the surrounding tissue in the body 
 Function appropriately in long-term 
Orthopedics 
Clin ical case reports in the treatment of orthopedic 
conditions have been reported. To date, the focus in the 
literature for musculoskeletal care appears to be on 
mesenchymal stem cells. Centeno et al. have published 
MRI ev idence of increased cartilage and meniscus volume 
in ind ividual human subjects.
35
 
36
 The results of trials 
including more patients are yet to be published making it  
hard to extrapolate the generalizab ility of these case 
reports. A newly published safety study published by the 
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same group shows good safety and fewer complications 
than surgical care in a large study group of 227 patients 
over a 3-4 year period. 
15 
Wakitani has also published a 
small case series of nine defects in five knees involving 
surgical transplantation of mesenchymal stem cells with 
coverage of the treated chondral defects.
37 
Wound healing 
In one experimental method in regenerative medicine, 
stem cells are used to stimulate the growth of human 
tissues. In an adult, wounded tissue is most often replaced 
by scar tissue, which is characterized in the skin by 
disorganized collagen structure, loss of hair follicles and 
irregular vascular structure. In the case of wounded fetal 
tissue, however, wounded tissue is replaced with normal 
tissue through the activity of stem cells.
38
 A possible 
method for t issue regeneration in adults is to place adult 
stem cell "seeds" inside a tissue bed "soil" in a wound bed 
and allow the stem cells to stimulate differentiation in the 
tissue bed cells. This method elicits a regenerative 
response more similar to fetal wound-healing than adult 
scar tissue formation.  Researchers are still investigating 
different aspects of the "soil" tissue that are conducive to 
regeneration.
38 
Infertility 
Culture of human embryonic stem cells  in mitotically  
inactivated porcine ovarian fibroblasts  (POF) causes 
differentiation into germ cells (precursor cells of oocytes 
and spermatozoa), as evidenced by gene expression 
analysis.
39
 Human embryonic stem cells have been 
stimulated to form Spermatozoon-like cells, yet still 
slightly damaged or malformed. 
40
 It could potentially treat 
azoospermia .
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